Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 117 results for "Tecfidera Treated Patients"

Tecfidera demonstrates sustained efficacy in RRMS studies
European Pharmaceutical Review

TECFIDERA® data highlights benefit of early treatment in rela...

Biogen present new TECFIDERA (dimethyl fumarate) research at the 68th annual meeting of the American Academy of Neurology (AAN) in Vancouver, Canada. The data presented supports the value of dimethyl fumarate in the treatment of patients with ... Hospital Pharmacy Europe, 1 month ago
Tecfidera demonstrates sustained efficacy in RRMS studies European Pharmaceutical Review, 1 month ago

1 images for "Tecfidera Treated Patients"

European Pharmaceutical Review, 1 month ago
PRWeb Provides Prescription Coupons to Patients With Multiple Sclerosis: In Tandem With New Treatments

Presription Savings Card Atlantic City, NJ (PRWEB) April 19, 2016 Over 400,000 Americans live with Multiple Sclerosis (MS) every day. There are an estimated 10,000 new cases diagnosed each year. New therapies that slow the progression of ...
 PRWeb1 month ago FDA approves new Biogen multiple sclerosis drug  Boston Globe4 days ago

EMD Serono to Present Data Assessing Comparative Effectiveness of Rebif® (interferon beta-1a) vs. TECFIDERA® (dimethyl fumurate) at AAN Annual Meeting

_ A real-world assessment of relapse rates in patients with MS newly initiating self-injectable treatment with Rebif versus an oral disease-modifying therapy, as well as the clinical effect of Rebif on 'no evident disease activity' (NEDA) and MRI ...
 Sys-Con Media1 month ago

Controlling complicated psoriasis

Dermatologists and their patients have benefited immensely from the expanded armamentarium of treatment options for plaque psoriasis. Nevertheless, they may still be challenged by patients with coexisting systemic diseases or other psoriasis ...
 Dermatology Times1 month ago

Tecfidera Continues to Be Key Revenue Driver for Biogen in 1Q16

Strong Product Portfolio Drove Biogen's 1Q16 Profit Margins ( Continued from Prior Part ) Tecfidera performance By the end of 1Q16, Biogen's (BIIB) leading multiple sclerosis (or MS) drug, Tecfidera, had treated about 190,000 multiple ...
 Yahoo! Finance UK and Ireland1 month ago

New Study By Spherix Global Insights Indicates High Therapy Switching Rates For Multiple Sclerosis Patients In The US And EU, Benefitting Biogen's...

New Study By Spherix Global Insights Indicates High Therapy Switching Rates For Multiple Sclerosis Patients In The US And EU, Benefitting Biogen's Tecfidera, Novartis' Gilenya And Sanofi's Aubagio By a News Reporter-Staff News Editor at Pharma ...
 Equities.com1 month ago

February 2016 Tecfidera Label Change Adds Information About PML Risks

There seems to have been more Tecfidera progressive multifocal leukoencephalopathy (PML) cases reported in the past year or so. And it seems that lymphonpenia possibly induced by Tecfidera might have a role to play in those additional PML cases. ...
 DrugInjuryLaw.com2 weeks ago A Tecfidera Label Change Modifying Warnings About Progressive Multifocal Leukoencephalopathy (PML) Was Done In February 2016 With Little Notice  Drug Injury Watch2 weeks ago

Biotech Grw Tst PLC Final Results

25/05/2016 2:29pm UK Regulatory (RNS & others) TIDMBIOG LONDON STOCK EXCHANGE ANNOUNCEMENT The Biotech Growth Trust PLC Audited Results for the Year Ended 31 March 2016 The Company's annual ...
 ADVFN UK6 days ago THE BIOTECH GROWTH TRUST PLC - Final Results  Ariva.de6 days ago BIOTECH GROWTH : Final Results  4 Traders6 days ago

The Best Buys in Biopharma Today

Fight! Fight! Fight! In this week's episode of Industry Focus: Healthcare , Kristine Harjes and Todd Campbell pit four of the pharmaceutical industry's biggest drug companies against each other to weigh out today's best buys for healthcare ...
 Motley Fool1 week ago
Motley Fool

Gilead Has Great Value Now; No Need For It To Make A Big Deal

Introduction It's gotten to where I'm both thankful for the P/E of 7X or below in Gilead (NASDAQ: GILD ), but where I also want to say, from the disco era : Enough is enough is enough is enough is enough is enough I've had it... we've had ...
 Seeking Alpha1 week ago Better Buy: Gilead Sciences vs. Biogen  Motley Fool3 weeks ago Better Buy Gilead Sciences vs. Biogen  FOXBusiness.com3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less